IASO104 Car-t therapy for relapsed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy (IASO104) for people whose multiple myeloma has come back or not responded to other treatments. It aims to see if this therapy can help reduce or eliminate the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a confirmed diagnosis of multiple myeloma or primary plasma cell leukemia.
- You must have tried at least 3 prior treatments (or be resistant to certain drugs) for myeloma, or at least 1 prior treatment for primary plasma cell leukemia.
- Your disease must have progressed within 12 months after your last treatment (unless your last treatment was CAR-T).
- You need to have some measurable signs of disease, like a specific protein level in blood or urine, or a certain number of plasma cells in bone marrow.
- You should be in generally good health (able to care for yourself, adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called IASO206 for people with multiple myeloma that has come back or not responded to previous treatments. The therapy targets a protein called BCMA on myeloma cells, which may help control the disease.
This trial tests a new type of immune cell therapy (CAR-T cells boosted with a protein called IL-15) for people with multiple myeloma or plasma cell leukemia that has not responded to standard treatments or has come back. The goal is to see if these enhanced cells can better fight the cancer.
This study tests a two-step approach for people with relapsed or hard-to-treat multiple myeloma. First, you get a bispecific antibody (a drug that helps your immune system attack myeloma cells), then you receive CAR-T cell therapy (your own immune cells modified to fight the cancer). The goal is to see if this combination works well together.
This trial tests a new treatment called CAR-T cell therapy that uses your own immune cells to fight cancer. It is for people with multiple myeloma or plasma cell leukemia that has come back or not responded to other treatments.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This study tests a new type of immune cell therapy (CAR T-cells) for people with advanced multiple myeloma that has relapsed or not responded to standard treatments. The goal is to see if this therapy is safe and to understand its potential benefits.
Hear when a new Relapsed/Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.